PLoS Biology (Nov 2023)

Nonsense mutation suppression is enhanced by targeting different stages of the protein synthesis process.

  • Amnon Wittenstein,
  • Michal Caspi,
  • Ido Rippin,
  • Orna Elroy-Stein,
  • Hagit Eldar-Finkelman,
  • Sven Thoms,
  • Rina Rosin-Arbesfeld

DOI
https://doi.org/10.1371/journal.pbio.3002355
Journal volume & issue
Vol. 21, no. 11
p. e3002355

Abstract

Read online

The introduction of premature termination codons (PTCs), as a result of splicing defects, insertions, deletions, or point mutations (also termed nonsense mutations), lead to numerous genetic diseases, ranging from rare neuro-metabolic disorders to relatively common inheritable cancer syndromes and muscular dystrophies. Over the years, a large number of studies have demonstrated that certain antibiotics and other synthetic molecules can act as PTC suppressors by inducing readthrough of nonsense mutations, thereby restoring the expression of full-length proteins. Unfortunately, most PTC readthrough-inducing agents are toxic, have limited effects, and cannot be used for therapeutic purposes. Thus, further efforts are required to improve the clinical outcome of nonsense mutation suppressors. Here, by focusing on enhancing readthrough of pathogenic nonsense mutations in the adenomatous polyposis coli (APC) tumor suppressor gene, we show that disturbing the protein translation initiation complex, as well as targeting other stages of the protein translation machinery, enhances both antibiotic and non-antibiotic-mediated readthrough of nonsense mutations. These findings strongly increase our understanding of the mechanisms involved in nonsense mutation readthrough and facilitate the development of novel therapeutic targets for nonsense suppression to restore protein expression from a large variety of disease-causing mutated transcripts.